Literature DB >> 23077013

Prospective cohort study of spinal muscular atrophy types 2 and 3.

Petra Kaufmann1, Michael P McDermott, Basil T Darras, Richard S Finkel, Douglas M Sproule, Peter B Kang, Maryam Oskoui, Andrei Constantinescu, Clifton L Gooch, A Reghan Foley, Michele L Yang, Rabi Tawil, Wendy K Chung, William B Martens, Jacqueline Montes, Vanessa Battista, Jessica O'Hagen, Sally Dunaway, Jean Flickinger, Janet Quigley, Susan Riley, Allan M Glanzman, Maryjane Benton, Patricia A Ryan, Mark Punyanitya, Megan J Montgomery, Jonathan Marra, Benjamin Koo, Darryl C De Vivo.   

Abstract

OBJECTIVE: To characterize the natural history of spinal muscular atrophy type 2 and type 3 (SMA 2/3) beyond 1 year and to report data on clinical and biological outcomes for use in trial planning.
METHODS: We conducted a prospective observational cohort study of 79 children and young adults with SMA 2/3 who participated in evaluations for up to 48 months. Clinically, we evaluated motor and pulmonary function, quality of life, and muscle strength. We also measured SMN2 copy number, hematologic and biochemical profiles, muscle mass by dual x-ray absorptiometry (DXA), and the compound motor action potential (CMAP) in a hand muscle. Data were analyzed for associations between clinical and biological/laboratory characteristics cross-sectionally, and for change over time in outcomes using all available data.
RESULTS: In cross-sectional analyses, certain biological measures (specifically, CMAP, DXA fat-free mass index, and SMN2 copy number) and muscle strength measures were associated with motor function. Motor and pulmonary function declined over time, particularly at time points beyond 12 months of follow-up.
CONCLUSION: The intermediate and mild phenotypes of SMA show slow functional declines when observation periods exceed 1 year. Whole body muscle mass, hand muscle compound motor action potentials, and muscle strength are associated with clinical measures of motor function. The data from this study will be useful for clinical trial planning and suggest that CMAP and DXA warrant further evaluation as potential biomarkers.

Entities:  

Mesh:

Year:  2012        PMID: 23077013      PMCID: PMC3525313          DOI: 10.1212/WNL.0b013e318271f7e4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation.

Authors:  Marion Main; Harvey Kairon; Eugenio Mercuri; Francesco Muntoni
Journal:  Eur J Paediatr Neurol       Date:  2003       Impact factor: 3.140

2.  PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations.

Authors:  J W Varni; M Seid; P S Kurtin
Journal:  Med Care       Date:  2001-08       Impact factor: 2.983

3.  Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy.

Authors:  T-H Chen; J-G Chang; Y-H Yang; H-H Mai; W-C Liang; Y-C Wu; H-Y Wang; Y-B Huang; S-M Wu; Y-C Chen; S-N Yang; Y-J Jong
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

4.  Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.

Authors:  Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard Finkel; Peter Kang; Maryam Oskoui; Andrei Constantinescu; Douglas Michael Sproule; A Reghan Foley; Michele Yang; Rabi Tawil; Wendy Chung; Bill Martens; Jacqueline Montes; Jessica O'Hagen; Sally Dunaway; Jean M Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Carrie Irvine; Christine L Annis; Hailly Butler; Jayson Caracciolo; Megan Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo
Journal:  Arch Neurol       Date:  2011-02-14

5.  Prospective analysis of strength in spinal muscular atrophy. DCN/Spinal Muscular Atrophy Group.

Authors:  S T Iannaccone; B S Russman; R H Browne; C R Buncher; M White; F J Samaha
Journal:  J Child Neurol       Date:  2000-02       Impact factor: 1.987

6.  Outcome measures for pediatric spinal muscular atrophy.

Authors:  Susan T Iannaccone
Journal:  Arch Neurol       Date:  2002-09

7.  Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis.

Authors:  Thierry Bordet; Bruno Buisson; Magali Michaud; Cyrille Drouot; Pascale Galéa; Pierre Delaage; Natalia P Akentieva; Alex S Evers; Douglas F Covey; Mariano A Ostuni; Jean-Jacques Lacapère; Charbel Massaad; Michael Schumacher; Esther-Marie Steidl; Delphine Maux; Michel Delaage; Christopher E Henderson; Rebecca M Pruss
Journal:  J Pharmacol Exp Ther       Date:  2007-05-11       Impact factor: 4.030

8.  Height prediction from ulna length.

Authors:  Leanne M Gauld; Johanna Kappers; John B Carlin; Colin F Robertson
Journal:  Dev Med Child Neurol       Date:  2004-07       Impact factor: 5.449

9.  A phase 1 trial of riluzole in spinal muscular atrophy.

Authors:  Barry S Russman; Susan T Iannaccone; Frederick J Samaha
Journal:  Arch Neurol       Date:  2003-11

10.  Motor function-muscle strength relationship in spinal muscular atrophy.

Authors:  Luciano Merlini; Enrico Bertini; Carlo Minetti; Tiziana Mongini; Lucia Morandi; Corrado Angelini; Giuseppe Vita
Journal:  Muscle Nerve       Date:  2004-04       Impact factor: 3.217

View more
  63 in total

1.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

2.  Radiographic and Respiratory Effects of Growing Rods in Children With Spinal Muscular Atrophy.

Authors:  Rachel L Lenhart; Sylvester Youlo; Mary K Schroth; Kenneth J Noonan; James McCarthy; David Mann; Scott Hetzel; Sarah A Sund; Matthew A Halanski
Journal:  J Pediatr Orthop       Date:  2017-12       Impact factor: 2.324

Review 3.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

4.  Natural history of infantile-onset spinal muscular atrophy.

Authors:  Stephen J Kolb; Christopher S Coffey; Jon W Yankey; Kristin Krosschell; W David Arnold; Seward B Rutkove; Kathryn J Swoboda; Sandra P Reyna; Ai Sakonju; Basil T Darras; Richard Shell; Nancy Kuntz; Diana Castro; Julie Parsons; Anne M Connolly; Claudia A Chiriboga; Craig McDonald; W Bryan Burnette; Klaus Werner; Mathula Thangarajh; Perry B Shieh; Erika Finanger; Merit E Cudkowicz; Michelle M McGovern; D Elizabeth McNeil; Richard Finkel; Susan T Iannaccone; Edward Kaye; Allison Kingsley; Samantha R Renusch; Vicki L McGovern; Xueqian Wang; Phillip G Zaworski; Thomas W Prior; Arthur H M Burghes; Amy Bartlett; John T Kissel
Journal:  Ann Neurol       Date:  2017-12-08       Impact factor: 10.422

Review 5.  Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain.

Authors:  Charlotte J Sumner; Thomas O Crawford
Journal:  J Clin Invest       Date:  2018-07-09       Impact factor: 14.808

6.  Resistance strength training exercise in children with spinal muscular atrophy.

Authors:  Aga Lewelt; Kristin J Krosschell; Gregory J Stoddard; Cindy Weng; Mei Xue; Robin L Marcus; Eduard Gappmaier; Louis Viollet; Barbara A Johnson; Andrea T White; Donata Viazzo-Trussell; Philippe Lopes; Robert H Lane; John C Carey; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2015-10       Impact factor: 3.217

7.  The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.

Authors:  W Arnold; Vicki L McGovern; Benjamin Sanchez; Jia Li; Kaitlyn M Corlett; Stephen J Kolb; Seward B Rutkove; Arthur H Burghes
Journal:  Neurobiol Dis       Date:  2015-12-28       Impact factor: 5.996

8.  Observational study of spinal muscular atrophy type I and implications for clinical trials.

Authors:  Richard S Finkel; Michael P McDermott; Petra Kaufmann; Basil T Darras; Wendy K Chung; Douglas M Sproule; Peter B Kang; A Reghan Foley; Michelle L Yang; William B Martens; Maryam Oskoui; Allan M Glanzman; Jean Flickinger; Jacqueline Montes; Sally Dunaway; Jessica O'Hagen; Janet Quigley; Susan Riley; Maryjane Benton; Patricia A Ryan; Megan Montgomery; Jonathan Marra; Clifton Gooch; Darryl C De Vivo
Journal:  Neurology       Date:  2014-07-30       Impact factor: 9.910

9.  The motor neuron response to SMN1 deficiency in spinal muscular atrophy.

Authors:  Peter B Kang; Clifton L Gooch; Michael P McDermott; Basil T Darras; Richard S Finkel; Michele L Yang; Douglas M Sproule; Wendy K Chung; Petra Kaufmann; Darryl C de Vivo
Journal:  Muscle Nerve       Date:  2014-05       Impact factor: 3.217

10.  Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.

Authors:  Wendy K M Liew; Peter B Kang
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.